These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28130839)

  • 1. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour.
    Schaefer IM; Hornick JL; Sholl LM; Quade BJ; Nucci MR; Parra-Herran C
    Histopathology; 2017 Jun; 70(7):1138-1146. PubMed ID: 28130839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
    Chen L; Yang B
    Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
    Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
    Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
    Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
    Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry (Ki-67 and p53) as a tool in determining malignancy in smooth muscle neoplasms (exemplified by a myxoid leiomyosarcoma of the uterus).
    Sprogøe-Jakobsen S; Hølund B
    APMIS; 1996 Oct; 104(10):705-8. PubMed ID: 8980620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory Myofibroblastic Tumor of the Uterus: An Immunohistochemical Study of 23 Cases.
    Bennett JA; Croce S; Pesci A; Niu N; Van de Vijver K; Burks EJ; Burandt E; Zannoni GF; Rabban JT; Oliva E
    Am J Surg Pathol; 2020 Nov; 44(11):1441-1449. PubMed ID: 32568825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
    Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
    Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma.
    Liang Y; Zhang X; Chen X; Lü W
    Int J Clin Exp Pathol; 2015; 8(6):7196-202. PubMed ID: 26261614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel PLAG1 Gene Rearrangement Distinguishes a Subset of Uterine Myxoid Leiomyosarcoma From Other Uterine Myxoid Mesenchymal Tumors.
    Arias-Stella JA; Benayed R; Oliva E; Young RH; Hoang LN; Lee CH; Jungbluth AA; Frosina D; Soslow RA; Antonescu CR; Ladanyi M; Chiang S
    Am J Surg Pathol; 2019 Mar; 43(3):382-388. PubMed ID: 30489320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
    Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
    Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors.
    Ptáková N; Miesbauerová M; Kosťun J; Grossmann P; Šidlová H; Pavelka J; Presl J; Alaghehbandan R; Bouda J; Ondič O
    Virchows Arch; 2018 Nov; 473(5):583-590. PubMed ID: 30116888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myxoid Leiomyosarcoma of the Uterus: A Clinicopathologic Analysis of 30 Cases and Review of the Literature With Reappraisal of Its Distinction From Other Uterine Myxoid Mesenchymal Neoplasms.
    Parra-Herran C; Schoolmeester JK; Yuan L; Dal Cin P; Fletcher CD; Quade BJ; Nucci MR
    Am J Surg Pathol; 2016 Mar; 40(3):285-301. PubMed ID: 26866354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory myofibroblastic tumor of the uterus - case report.
    Štiková Z; Ptáková N; Horáková M; Kosťun J; Ondič O
    Cesk Patol; 2019; 55(4):239-243. PubMed ID: 31842556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas.
    Mittal KR; Chen F; Wei JJ; Rijhvani K; Kurvathi R; Streck D; Dermody J; Toruner GA
    Mod Pathol; 2009 Oct; 22(10):1303-11. PubMed ID: 19633649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myxoid Mesenchymal Tumors of the Uterus: An Update on Classification, Definitions, and Differential Diagnosis.
    Busca A; Parra-Herran C
    Adv Anat Pathol; 2017 Nov; 24(6):354-361. PubMed ID: 28787279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
    Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
    Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas.
    Fernandez-Flores A; Monteagudo C
    Ann Diagn Pathol; 2016 Oct; 24():25-9. PubMed ID: 27649950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of CDKN2A Promoter Methylation Coincides With the Epigenetic Transdifferentiation of Uterine Myosarcomatous Cells.
    Roncati L; Barbolini G; Sartori G; Siopis E; Pusiol T; Maiorana A
    Int J Gynecol Pathol; 2016 Jul; 35(4):309-15. PubMed ID: 27276112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma.
    Cornejo K; Shi M; Jiang Z
    Hum Pathol; 2012 Oct; 43(10):1567-72. PubMed ID: 22497850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.